<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04932512</url>
  </required_header>
  <id_info>
    <org_study_id>ION224-CS2</org_study_id>
    <nct_id>NCT04932512</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224</brief_title>
  <official_title>An Adaptive Two-Part Phase 2, Multi-Center, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224 Administered Once Monthly in Adult Subjects With Confirmed Non-Alcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of multiple ION224 doses when administered&#xD;
      by subcutaneous (SC) injection for 49 weeks (end of the treatment [EOT]) on non-alcoholic&#xD;
      steatohepatitis (NASH) histologic improvement and to assess the effect on liver steatosis by&#xD;
      magnetic resonance imaging-determined proton density fat fraction (MRI-PDFF), additional&#xD;
      changes in NASH histologic features, liver biochemistry tests, and plasma lipid profile.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, double-blind, randomized, placebo-controlled study of ION224 in up to 150&#xD;
      participants. The study consists of 3 periods: 1) Screening Period: Week -8 to Week -1 (up to&#xD;
      8 weeks); 2) Treatment Period up to Week 49; and 3) Post-Treatment Period: Week 50 to Week 62&#xD;
      (12 weeks).&#xD;
&#xD;
      Initially, 48 patients will be enrolled in three different dose cohorts to receive ION224 or&#xD;
      placebo every four weeks for 13 weeks. Based on safety and effects on liver steatosis&#xD;
      (assessed at Week 15), two dose cohorts will be selected to be expanded. After dose&#xD;
      selection, an additional 102 patients will be enrolled in the 2 selected dose cohorts and&#xD;
      will receive ION224 or placebo for up to 49 weeks. Participants in the 3rd cohort (not&#xD;
      selected) will continue to complete up to 49 weeks of treatment without any cohort expansion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 2-point Reduction in Non-alcoholic Fatty Liver Disease Activity Score (NAS) With at least 1-point Improvement in Hepatocellular Ballooning or Lobular Inflammation, and Without Worsening in Fibrosis Stage at EOT</measure>
    <time_frame>Up to Week 49</time_frame>
    <description>The NAS is a histology grading score composed on the assessment of steatosis (scale 0-3), hepatocellular ballooning (scale 0-2), and lobular inflammation (scale 0-3), with higher scores indicating more severe hepatitis. Worsening of fibrosis is defined as an increase in fibrosis of at least one stage on the Kleiner fibrosis classification: fibrosis stages range from 0-4, with higher scores indicating greater fibrosis (0=None, 4=Cirrhosis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hepatic Fat Content Measurement as Evaluated by MRI-PDFF and Calculated by an Independent, Blinded-To-Treatment, Central Reader</measure>
    <time_frame>Baseline up to Week 15, Week 29 and Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Non-alcoholic Steatohepatitis (NASH) Resolution, as Defined by Scores of 0 for Both Ballooning and Inflammation by the NAS, and Without Worsening of Fibrosis, Assessed Through Liver Biopsy at the EOT</measure>
    <time_frame>Up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Reduction of at Least 1 Stage in the Fibrosis Score, and Without Worsening of Steatohepatitis by the NAS, Assessed Through Liver Biopsy at the EOT</measure>
    <time_frame>Up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Combination of NASH Resolution and a 1 Stage Improvement in Fibrosis at the EOT</measure>
    <time_frame>Up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Less than or Equal to (≤) 1.5 Upper Limit of Normal (ULN) at the EOT</measure>
    <time_frame>Up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Liver-related Laboratory Test - ALT</measure>
    <time_frame>Baseline up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Liver-related Laboratory Test - AST</measure>
    <time_frame>Baseline up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Liver-related Laboratory Test - Total Bilirubin</measure>
    <time_frame>Baseline up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Liver-related Laboratory Test - Gamma-glutamyl Transferase</measure>
    <time_frame>Baseline up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Plasma Fasting Lipid Profile Test - Triglyceride (TG)</measure>
    <time_frame>Baseline up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Plasma Fasting Lipid Profile Test - Total Cholesterol</measure>
    <time_frame>Baseline up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Plasma Fasting Lipid Profile Test - Low-density Lipoprotein-cholesterol (LDL-c)</measure>
    <time_frame>Baseline up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Plasma Fasting Lipid Profile Test - High-density Lipoprotein-cholesterol (HDL-c)</measure>
    <time_frame>Baseline up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of ION224 and Metabolites</measure>
    <time_frame>Baseline up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of ION224 and Metabolites</measure>
    <time_frame>Baseline up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC) of ION224 and Metabolites</measure>
    <time_frame>Baseline up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Half-life (t½) of ION224 and Metabolites</measure>
    <time_frame>Baseline up to Week 49</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Steatohepatitis, Nonalcoholic</condition>
  <arm_group>
    <arm_group_label>ION224</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of ION224 will be administered by SC injection once every 4 weeks for up to 49 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of matching placebo will be administered by SC injection once every 4 weeks for up to 49 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ION224</intervention_name>
    <description>ION224 will be administered by SC injection.</description>
    <arm_group_label>ION224</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>ION224-matching placebo solution will be administered by SC injection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females greater than or equal to (≥) 18 and less than or equal to (≤) 75&#xD;
             years old at the time of informed consent.&#xD;
&#xD;
          -  Body mass index ≥ 25 Kg/m2 as assessed during screening&#xD;
&#xD;
          -  Liver fat ≥ 10% as assessed by MRI-PDFF before randomization.&#xD;
&#xD;
          -  Presence of NASH confirmed by centrally read liver biopsy&#xD;
&#xD;
          -  Weight loss &lt; 5% after historical biopsy. Otherwise, weight loss &lt; 5% in the previous&#xD;
             3 months prior to randomization.&#xD;
&#xD;
          -  ALT and AST ≤ 200 units per liter (U/L) and confirmed to be stable.&#xD;
&#xD;
          -  Total Bilirubin ≤ 1.3 miligrams per deciliter (mg/dL) and confirmed to be stable.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior or planned (during the Study Period) bariatric surgery&#xD;
&#xD;
          -  History of solid organ transplant&#xD;
&#xD;
          -  Screening laboratory values that would render a participant unsuitable for inclusion,&#xD;
             including but not limited to:&#xD;
&#xD;
               -  Clinically significant albuminuria or proteinuria&#xD;
&#xD;
               -  Positive test for blood on urinalysis&#xD;
&#xD;
               -  Estimated glomerular filtration rate (eGFR) &lt; 60 milliliters (mL)/minute&#xD;
                  (min)/1.73 square meter (m^2)&#xD;
&#xD;
               -  Hemoglobin A1c (HbA1c) &gt; 9.5%&#xD;
&#xD;
               -  Platelet count &lt; 170 × 10^9/liter (L)&#xD;
&#xD;
          -  Diagnosis of Gilbert's syndrome&#xD;
&#xD;
          -  Known history of or evidence of liver disease other than NASH.&#xD;
&#xD;
          -  Clinical evidence of liver decompensation&#xD;
&#xD;
          -  Active SARS-CoV-2 infection (COVID-19) or confirmed SARS-CoV-2 infection-related&#xD;
             complication within 8 weeks of Screening&#xD;
&#xD;
          -  Uncontrolled arterial hypertension&#xD;
&#xD;
          -  History of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Participants with known intolerance to magnetic resonance imaging (MRI) or with&#xD;
             conditions contraindicated for MRI Procedures&#xD;
&#xD;
          -  History of, or current hard drug or alcohol abuse within 2 years prior to Screening&#xD;
&#xD;
          -  Use of drugs historically associated with NAFLD for more than 2 weeks in the year&#xD;
             prior to Screening.&#xD;
&#xD;
          -  Use of obeticholic acid, ursodeoxycholic acid, icosapent ethyl, niacin, PCSK9&#xD;
             inhibitors, and bile acid sequestrants&#xD;
&#xD;
          -  Participants taking the following medicines UNLESS on a stable dose:&#xD;
&#xD;
               -  Anti-diabetic medications&#xD;
&#xD;
               -  statins, fenofibrate, and ezetimibe&#xD;
&#xD;
               -  Estrogen containing contraceptives&#xD;
&#xD;
               -  Glucagon-like peptide (GLP)-1 agonists&#xD;
&#xD;
               -  Pioglitazone&#xD;
&#xD;
               -  Vitamin E at doses ≤ 800 international unit (IU)/day&#xD;
&#xD;
               -  Herbal medicines, other prescription medicines, vitamins or supplements known to&#xD;
                  affect lipid metabolism&#xD;
&#xD;
          -  Other protocol-defined inclusion/exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ionis Pharmaceuticals</last_name>
    <phone>(844) 265-4363</phone>
    <email>ionisNCT04932512study@clinicaltrialmedia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Liver Health-Chandler</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arizona Liver Health</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arizona Liver Health</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arkansas Gastroenterology - North Little Rock</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GW Research, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Gardena</name>
      <address>
        <city>Gardena</city>
        <state>California</state>
        <zip>90247</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Research Institute Panorama City</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Santa Ana</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Denver Gastroenterology, PC</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>RecioMed Clinical Research Network, Inc.</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Medical Research, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Floridian Clinical Research, LLC.</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma CR, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metabolic Research Institute, Inc.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists of Georgia</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tandem Clinical Research GI, LLC.</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Louisiana Research Center, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern Therapy &amp; Advanced Research</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clarity Clinical Research</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cumberland Research Associates, LLC</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aventiv Research, Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Crioh, Llc</name>
      <address>
        <city>Westlake</city>
        <state>Ohio</state>
        <zip>44145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DHR Health Institute for Research and Development</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manassas Clinical Research Center</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FDI Clinical Research</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Alcoholic Steatohepatitis</keyword>
  <keyword>Non-alcoholic Fatty Liver Disease Activity Score</keyword>
  <keyword>Alanine Aminotransferase</keyword>
  <keyword>Aspartate Aminotransferase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

